Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas
Open Access
- 22 June 2007
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 7 (1) , 106
Abstract
To assess progression-free survival (PFS) as the appropriate end-point for phase II trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III trials.Keywords
This publication has 39 references indexed in Scilit:
- Treatment of Recurrent Gliomas With EflornithineJNCI: Journal of the National Cancer Institute, 1992
- A phase II study of cisplatin therapy in recurrent childhood brain tumorsJournal of Neuro-Oncology, 1989
- A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumorsJournal of Neuro-Oncology, 1988
- A Phase II Trial of Oral Melphalan in Recurrent Primary Brain TumorsAmerican Journal of Clinical Oncology, 1988
- Computerized tomography in the prognosis of malignant cerebral gliomasJournal of Neurosurgery, 1986
- Epidemiology of brain tumorsNeurology, 1985
- Treatment of patients with recurrent primary brain tumors with AZQNeurology, 1984
- Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeabilityJournal of Medicinal Chemistry, 1980
- Criteria for evaluating patients undergoing chemotherapy for malignant brain tumorsJournal of Neurosurgery, 1977
- Brain-tumor therapyJournal of Neurosurgery, 1977